{"id":"W2170362988","doi":"10.1093/annonc/mdl316","title":"A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150","year":2006,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; Queen's University; University Health Network; Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Mantle cell lymphoma; Bortezomib; Discontinuation; Internal medicine; Adverse effect; Toxicity; Clinical trial; Surgery; Lymphoma; Multiple myeloma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001490358,0.001244747,0.00163048,0.0003274682,0.0006324358,0.0009237204,0.000908375,0.001347315,0.006547622],"category_scores_gemma":[0.001246054,0.0003832366,0.001197418,0.0005445913,0.0008515936,0.0004329865,0.0003488481,0.002519674,0.001144327],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00286494,"about_ca_system_score_gemma":0.005646744,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.05869677,"about_ca_topic_score_gemma":0.1906572,"domain_scores_codex":[0.9995186,0.0002355539,0.00001576317,0.00004764633,0.00006980925,0.0001125781],"domain_scores_gemma":[0.9992417,0.0001307596,0.0001021846,0.00005129087,0.00006833355,0.0004056317],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8514657,0.008992986,0.004312773,0.001153033,0.002359659,0.0002086866,0.0002048388,0.001167358,0.008525121,0.0007785255,0.02632037,0.09451087],"study_design_scores_gemma":[0.9299982,0.04366953,0.01423126,0.00008570502,0.0009294474,0.0001270297,0.00005870909,0.0004959443,0.0005921433,0.0004072442,0.009373864,0.0000309523],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9302873,0.01942551,0.000729287,0.005724669,0.0005926032,0.007256513,0.0136748,0.0002109466,0.0220983],"genre_scores_gemma":[0.9540472,0.008791076,0.002699187,0.006926392,0.0003952518,0.004442792,0.008789638,0.0000668968,0.0138417],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05869677,"threshold_uncertainty_score":0.1167102,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2385970567865029,"score_gpt":0.5021967957604048,"score_spread":0.2635997389739019,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}